Research progress of fetuin B and coronary artery disease_West China Medical Journal

Authors：

LI Fandan ^1,2 , XU Jing ¹ , CHEN Yun ¹ ,  LÜ Zhan ¹

1. Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
2. Graduate School of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding author：

LÜ Zhan, Email: Doctor_LZ@163.com

Keywords：

Fetuin B; coronary artery disease; atherosclerosis; lipid metabolism; inflammation

DOI：

10.7507/1002-0179.202405135

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Coronary artery disease (CAD) is a cardiovascular disease mainly caused by atherosclerosis, which involves a variety of pathophysiological mechanisms such as lipid metabolism, inflammatory response, and endothelial dysfunction. Fetuin B is a glycoprotein secreted by the liver, which can participate in many processes such as cell inflammation, vascular calcification, and lipid metabolism, and is closely related to the pathogenesis of CAD. This article reviews the relationship between fetuin B and CAD and the mechanism of its occurrence and development, in order to provide new choices and methods for the prevention, diagnosis, and treatment of CAD.

Citation： LI Fandan, XU Jing, CHEN Yun, LÜ Zhan. Research progress of fetuin B and coronary artery disease. West China Medical Journal, 2024, 39(8): 1314-1318. doi: 10.7507/1002-0179.202405135 Copy

1.	Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol, 2019, 234(10): 16812-16823.
2.	Shao C, Wang J, Tian J, et al. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol, 2020, 1177: 1-36.
3.	Liu X, Shao Y, Han L, et al. Emerging evidence linking the liver to the cardiovascular system: liver-derived secretory factors. J Clin Transl Hepatol, 2023, 11(5): 1246-1255.
4.	Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J, 2000, 350 (Pt 2): 589-597.
5.	Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, et al. The structure, biosynthesis, and biological roles of fetuin-A: a review. Front Cell Dev Biol, 2022, 10: 945287.
6.	Afrisham R, Paknejad M, Ilbeigi D, et al. Positive correlation between circulating fetuin-A and severity of coronary artery disease in men. Endocr Metab Immune Disord Drug Targets, 2021, 21(2): 338-344.
7.	Gao T, Liu R, Li C, et al. Evaluation of the correlation between fetuin-B levels and essential hypertension: a cross-sectional study. Endocr Connect, 2023, 12(12): e230172.
8.	Olkowicz M, Czyzynska-Cichon I, Szupryczynska N, et al. Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans. J Transl Med, 2021, 19(1): 6.
9.	Li Z, He C, Liu Y, et al. Association of fetuin-B with subclinical atherosclerosis in obese Chinese adults. J Atheroscler Thromb, 2020, 27(5): 418-428.
10.	Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med, 2022, 9: 793405.
11.	Shaya GE, Leucker TM, Jones SR, et al. Coronary heart disease risk: low-density lipoprotein and beyond. Trends Cardiovasc Med, 2022, 32(4): 181-194.
12.	Damluji AA, Forman DE, Wang TY, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation, 2023, 147(3): e32-e62.
13.	Zhu K, Wang Y, Shu P, et al. Increased serum levels of fetuin B in patients with coronary artery disease. Endocrine, 2017, 58(1): 97-105.
14.	Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol, 2023, 14: 1190934.
15.	胡永毅, 冯力, 韩莹, 等. 胎球蛋白 B 和锁链素与冠心病患者心血管事件发生的相关性研究. 中国医药科学, 2020, 10(8): 223-225, 236.
16.	Gibbons RJ. Myocardial ischemia in the management of chronic coronary artery disease: past and present. Circ Cardiovasc Imaging, 2021, 14(1): e011615.
17.	Xing W, Tan Y, Li K, et al. Upregulated hepatokine fetuin B aggravates myocardial ischemia/reperfusion injury through inhibiting insulin signaling in diabetic mice. J Mol Cell Cardiol, 2021, 151: 163-172.
18.	Duggan JP, Peters AS, Trachiotis GD, et al. Epidemiology of coronary artery disease. Surg Clin North Am, 2022, 102(3): 499-516.
19.	Chyu KY, Dimayuga PC, Shah PK. Immunogenetics of atherosclerosis-link between lipids, immunity, and genes. Curr Atheroscler Rep, 2020, 22(10): 53.
20.	Zhou W, Yang J, Zhu J, et al. Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice. Am J Transl Res, 2019, 11(3): 1498-1509.
21.	Handelman SK, Puentes YM, Kuppa A, et al. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids. Hepatol Commun, 2022, 6(11): 3120-3131.
22.	Boland J, Long C. Update on the inflammatory hypothesis of coronary artery disease. Curr Cardiol Rep, 2021, 23(2): 6.
23.	Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity (Silver Spring), 2024, 32(3): 517-527.
24.	Zhang W, Yao J, Chen C, et al. Fetuin-B overexpression promotes inflammation in diabetic retinopathy through activating microglia and the NF-κB signaling pathway. Curr Eye Res, 2024, 49(2): 168-179.
25.	Pan W, Jie W, Huang H. Vascular calcification: molecular mechanisms and therapeutic interventions. MedComm (2020), 2023, 4(1): e200.
26.	Herrmann M, Babler A, Moshkova I, et al. Lumenal calcification and microvasculopathy in fetuin-A-deficient mice lead to multiple organ morbidity. PLoS One, 2020, 15(2): e0228503.
27.	Denecke B, Gräber S, Schäfer C, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J, 2003, 376(Pt 1): 135-145.
28.	Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci, 2021, 22(8): 3850.
29.	Wang D, Wu M, Zhang X, et al. Hepatokine fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity. Sci Rep, 2022, 12(1): 12869.
30.	Jung SH, Lee D, Jin H, et al. Fetuin-B regulates vascular plaque rupture via TGF-β receptor-mediated Smad pathway in vascular smooth muscle cells. Pflugers Arch, 2020, 472(5): 571-581.
31.	Henein MY, Vancheri S, Longo G, et al. The role of inflammation in cardiovascular disease. Int J Mol Sci, 2022, 23(21): 12906.

1. Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol, 2019, 234(10): 16812-16823.
2. Shao C, Wang J, Tian J, et al. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol, 2020, 1177: 1-36.
3. Liu X, Shao Y, Han L, et al. Emerging evidence linking the liver to the cardiovascular system: liver-derived secretory factors. J Clin Transl Hepatol, 2023, 11(5): 1246-1255.
4. Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J, 2000, 350 (Pt 2): 589-597.
5. Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, et al. The structure, biosynthesis, and biological roles of fetuin-A: a review. Front Cell Dev Biol, 2022, 10: 945287.
6. Afrisham R, Paknejad M, Ilbeigi D, et al. Positive correlation between circulating fetuin-A and severity of coronary artery disease in men. Endocr Metab Immune Disord Drug Targets, 2021, 21(2): 338-344.
7. Gao T, Liu R, Li C, et al. Evaluation of the correlation between fetuin-B levels and essential hypertension: a cross-sectional study. Endocr Connect, 2023, 12(12): e230172.
8. Olkowicz M, Czyzynska-Cichon I, Szupryczynska N, et al. Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans. J Transl Med, 2021, 19(1): 6.
9. Li Z, He C, Liu Y, et al. Association of fetuin-B with subclinical atherosclerosis in obese Chinese adults. J Atheroscler Thromb, 2020, 27(5): 418-428.
10. Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med, 2022, 9: 793405.
11. Shaya GE, Leucker TM, Jones SR, et al. Coronary heart disease risk: low-density lipoprotein and beyond. Trends Cardiovasc Med, 2022, 32(4): 181-194.
12. Damluji AA, Forman DE, Wang TY, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation, 2023, 147(3): e32-e62.
13. Zhu K, Wang Y, Shu P, et al. Increased serum levels of fetuin B in patients with coronary artery disease. Endocrine, 2017, 58(1): 97-105.
14. Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol, 2023, 14: 1190934.
15. 胡永毅, 冯力, 韩莹, 等. 胎球蛋白 B 和锁链素与冠心病患者心血管事件发生的相关性研究. 中国医药科学, 2020, 10(8): 223-225, 236.
16. Gibbons RJ. Myocardial ischemia in the management of chronic coronary artery disease: past and present. Circ Cardiovasc Imaging, 2021, 14(1): e011615.
17. Xing W, Tan Y, Li K, et al. Upregulated hepatokine fetuin B aggravates myocardial ischemia/reperfusion injury through inhibiting insulin signaling in diabetic mice. J Mol Cell Cardiol, 2021, 151: 163-172.
18. Duggan JP, Peters AS, Trachiotis GD, et al. Epidemiology of coronary artery disease. Surg Clin North Am, 2022, 102(3): 499-516.
19. Chyu KY, Dimayuga PC, Shah PK. Immunogenetics of atherosclerosis-link between lipids, immunity, and genes. Curr Atheroscler Rep, 2020, 22(10): 53.
20. Zhou W, Yang J, Zhu J, et al. Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice. Am J Transl Res, 2019, 11(3): 1498-1509.
21. Handelman SK, Puentes YM, Kuppa A, et al. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids. Hepatol Commun, 2022, 6(11): 3120-3131.
22. Boland J, Long C. Update on the inflammatory hypothesis of coronary artery disease. Curr Cardiol Rep, 2021, 23(2): 6.
23. Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity (Silver Spring), 2024, 32(3): 517-527.
24. Zhang W, Yao J, Chen C, et al. Fetuin-B overexpression promotes inflammation in diabetic retinopathy through activating microglia and the NF-κB signaling pathway. Curr Eye Res, 2024, 49(2): 168-179.
25. Pan W, Jie W, Huang H. Vascular calcification: molecular mechanisms and therapeutic interventions. MedComm (2020), 2023, 4(1): e200.
26. Herrmann M, Babler A, Moshkova I, et al. Lumenal calcification and microvasculopathy in fetuin-A-deficient mice lead to multiple organ morbidity. PLoS One, 2020, 15(2): e0228503.
27. Denecke B, Gräber S, Schäfer C, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J, 2003, 376(Pt 1): 135-145.
28. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci, 2021, 22(8): 3850.
29. Wang D, Wu M, Zhang X, et al. Hepatokine fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity. Sci Rep, 2022, 12(1): 12869.
30. Jung SH, Lee D, Jin H, et al. Fetuin-B regulates vascular plaque rupture via TGF-β receptor-mediated Smad pathway in vascular smooth muscle cells. Pflugers Arch, 2020, 472(5): 571-581.
31. Henein MY, Vancheri S, Longo G, et al. The role of inflammation in cardiovascular disease. Int J Mol Sci, 2022, 23(21): 12906.

West China Medical Journal

Research progress of fetuin B and coronary artery disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content